Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Try arivis for free

30-day free trial offers a number of benefits.

Meeting with focus on South Korea and Japan’s life sciences

Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...

Efficient use of blood plasma

Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

Automated opening and closing of sample vials

From technical requirements to a suitable solution

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

Mavatar AB

Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”

”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain mar...

Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”

How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cl...

He is heading a new company for the development of Coegin’s cancer drug

The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

Column: ”We need to exploit the benefits of the regulations“

You don’t need to search long on the Internet to find lists of the most innovative countries with Sweden ranking at the top. Sweden generally offers good condit...

Enabling 3D Multiplexing Spatial Omics Workflows in Neuroscience

Case study by ZEISS Microscopy.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas

Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...

The Covid pandemic accelerated the development of cancer vaccine

The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast ...

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

High biological age is linked to a higher risk of dementia and stroke

It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher tha...

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Trumps ”lösning” på autismgåtan får forskare att skaka på huvudet

Användandet av paracetamol under graviditeten pekas av USA:s president Donald Trump ut som boven bakom autism, medan ett annat läkemedel med folinsyra – ett sla...

How Volume EM Advances Life Science Research

Free webinar series.